NXERA PHARMA CO., LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,480 JPY | +0.82% |
|
-2.12% | +4.01% |
| 04-18 | Nxera Pharma Initiates Restricted Stock Unit Plans, Starting with Shares Worth 164 Million Yen in Total in May | MT |
| 04-17 | Nxera Pharma's Neuro Drug NBI-1117568 Passed Preclinical Toxicity Test | MT |
Presenter SpeechHironoshin Nomura (Executives)[Interpreted] Time has come, so we would now lik...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Nxera Pharma Co Ltd, formerly known as Sosei Group Corp, is a Japan-based company engaged in the biopharmaceutical business that handles from drug research (drug discovery) to development and sale. The Company is mainly engaged in the pharmaceutical business. The Company is engaged in drug discovery, translational medicine, preclinical and early clinical development, as well as the research and development, import/export, packaging, and sale of pharmaceuticals. The Company also conducts structural analysis of G protein-coupled receptors (GPCRs), creates initial lead compounds, and searches for candidate products using StaR technology.
Sector
Pharmaceuticals
Calendar
2024-08-07
- Q2 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1,468
JPY
Average target price
2,100
JPY
Spread / Average Target
+43.05%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +4.01% | 849M | |
| -2.55% | 90.45B | |
| +3.68% | 41.45B | |
| -10.90% | 33.57B | |
| +58.05% | 25.73B | |
| -19.56% | 14.73B | |
| -9.06% | 12.82B | |
| -11.34% | 11.7B | |
| -43.53% | 11.44B | |
| +3.75% | 8.79B |
- Stock Market
- Equities
- 4565 Stock
- News Nxera Pharma Co., Ltd.
- Transcript : Sosei Group Corporation, Q2 2023 Earnings Call, Aug 04, 2023